MYCN and neuroblastoma: Here, a panel of MYCN-amplified/expressing and non-amplified/expressing NB tumour cell lines were screened for reduced viability in the presence of the PARP inhibitors olaparib (AZD-2281) and niraparib (MK-4827) (Figure 1A and Supplementary Figure 1).